Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $3.5 million.

  • Medifast's Depreciation & Amortization (CF) rose 879.12% to $3.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.2 million, marking a year-over-year increase of 1208.0%. This contributed to the annual value of $14.2 million for FY2025, which is 1208.0% up from last year.
  • As of Q4 2025, Medifast's Depreciation & Amortization (CF) stood at $3.5 million, which was up 879.12% from $3.5 million recorded in Q3 2025.
  • Medifast's 5-year Depreciation & Amortization (CF) high stood at $4.0 million for Q2 2025, and its period low was $1.1 million during Q1 2021.
  • For the 5-year period, Medifast's Depreciation & Amortization (CF) averaged around $2.9 million, with its median value being $3.1 million (2024).
  • Examining YoY changes over the last 5 years, Medifast's Depreciation & Amortization (CF) showed a top increase of 42290.56% in 2021 and a maximum decrease of 3224.83% in 2021.
  • Over the past 5 years, Medifast's Depreciation & Amortization (CF) (Quarter) stood at $3.0 million in 2021, then fell by 2.99% to $3.0 million in 2022, then increased by 13.51% to $3.4 million in 2023, then decreased by 5.01% to $3.2 million in 2024, then grew by 8.79% to $3.5 million in 2025.
  • Its Depreciation & Amortization (CF) was $3.5 million in Q4 2025, compared to $3.5 million in Q3 2025 and $4.0 million in Q2 2025.